Otto J, Günther S, Urbanek R
Universitäts-Kinderklinik, Freiburg, Federal Republic of Germany.
Eur J Pediatr. 1990 Jun;149(9):661-4. doi: 10.1007/BF02034759.
The density (Bmax) and affinity (KD) of beta 2-adrenoceptors in polymorphonuclear leukocytes (PMN) were measured in 29 children and juveniles with mild or moderate asthma and in 25 healthy control subjects using the highly specific radioligand (+/-)-125I-cyanopindolol. No significant difference in Bmax was found between asthmatic subjects without medication and the control group. The asthmatic subjects were divided into four different groups by their actual medication: no medication, adrenergics, theophylline, adrenergics plus theophylline. Analysis of variance revealed highly significant differences between these groups for Bmax (P = 0.0016) but not for KD. In asthmatics on adrenergic therapy Bmax was significantly lower (995 +/- 415) than in asthmatics without medication (1660 +/- 521; P = 0.008). In contrast, Bmax in asthmatics on theophylline therapy was significantly higher (2137 +/- 231; P = 0.009) than in the controls. Bmax was average in the group of asthmatics treated with both adrenergics and theophylline (1619 +/- 547). It is concluded that in asthmatic subjects therapy with theophylline increases the density of beta 2-adrenoceptors and partly prevents their down-regulation induced by adrenergic therapy.
采用高特异性放射性配体(±)-125I-氰基吲哚洛尔,对29例轻、中度哮喘儿童和青少年以及25例健康对照者的多形核白细胞(PMN)中β2-肾上腺素能受体的密度(Bmax)和亲和力(KD)进行了测定。未用药的哮喘患者与对照组之间的Bmax无显著差异。根据实际用药情况,将哮喘患者分为四组:未用药组、肾上腺素能药物组、茶碱组、肾上腺素能药物加茶碱组。方差分析显示,这些组之间的Bmax差异极显著(P = 0.0016),而KD无差异。接受肾上腺素能药物治疗的哮喘患者的Bmax显著低于未用药的哮喘患者(995±415比1660±521;P = 0.008)。相反,接受茶碱治疗的哮喘患者的Bmax显著高于对照组(2137±231;P = 0.009)。接受肾上腺素能药物和茶碱联合治疗的哮喘患者组的Bmax处于平均水平(1619±547)。得出结论:在哮喘患者中,茶碱治疗可增加β2-肾上腺素能受体的密度,并部分预防肾上腺素能药物治疗引起的受体下调。